386 related articles for article (PubMed ID: 26789110)
1. Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma.
Ikeda S; Kitadate A; Ito M; Abe F; Nara M; Watanabe A; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2016 Mar; 7(12):13563-74. PubMed ID: 26789110
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma.
Ito M; Teshima K; Ikeda S; Kitadate A; Watanabe A; Nara M; Yamashita J; Ohshima K; Sawada K; Tagawa H
Blood; 2014 Mar; 123(10):1499-511. PubMed ID: 24385540
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
4. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
[TBL] [Abstract][Full Text] [Related]
5. DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway.
Guo W; Li H; Liu H; Ma X; Yang S; Wang Z
Oncol Rep; 2019 Sep; 42(3):1075-1089. PubMed ID: 31322256
[TBL] [Abstract][Full Text] [Related]
6. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
7. Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: An overview.
Frick VO; Rubie C; Keilholz U; Ghadjar P
World J Gastroenterol; 2016 Jan; 22(2):833-41. PubMed ID: 26811629
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma.
Matsuda Y; Ikeda S; Abe F; Takahashi Y; Kitadate A; Takahashi N; Wakui H; Tagawa H
Cancer Sci; 2022 Apr; 113(4):1208-1219. PubMed ID: 35133054
[TBL] [Abstract][Full Text] [Related]
9. The effects of the CCR6/CCL20 biological axis on the invasion and metastasis of hepatocellular carcinoma.
Du D; Liu Y; Qian H; Zhang B; Tang X; Zhang T; Liu W
Int J Mol Sci; 2014 Apr; 15(4):6441-52. PubMed ID: 24743888
[TBL] [Abstract][Full Text] [Related]
10. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
[TBL] [Abstract][Full Text] [Related]
11. BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma.
Esmailzadeh S; Huang Y; Su MW; Zhou Y; Jiang X
Leukemia; 2015 Jun; 29(6):1402-13. PubMed ID: 25578476
[TBL] [Abstract][Full Text] [Related]
12. The CCR6/CCL20 axis mediates Th17 cell migration to the ocular surface in dry eye disease.
Dohlman TH; Chauhan SK; Kodati S; Hua J; Chen Y; Omoto M; Sadrai Z; Dana R
Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):4081-91. PubMed ID: 23702781
[TBL] [Abstract][Full Text] [Related]
13. CCR6, the sole receptor for the chemokine CCL20, promotes spontaneous intestinal tumorigenesis.
Nandi B; Pai C; Huang Q; Prabhala RH; Munshi NC; Gold JS
PLoS One; 2014; 9(5):e97566. PubMed ID: 24866282
[TBL] [Abstract][Full Text] [Related]
14. lncRNA‑u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling.
Wei W; Zhao X; Zhu J; Zhang L; Chen Y; Zhang B; Li Y; Wang M; Zhang Z; Wang C
Oncol Rep; 2019 Nov; 42(5):1946-1956. PubMed ID: 31545478
[TBL] [Abstract][Full Text] [Related]
15. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model.
Hirota K; Yoshitomi H; Hashimoto M; Maeda S; Teradaira S; Sugimoto N; Yamaguchi T; Nomura T; Ito H; Nakamura T; Sakaguchi N; Sakaguchi S
J Exp Med; 2007 Nov; 204(12):2803-12. PubMed ID: 18025126
[TBL] [Abstract][Full Text] [Related]
16. CCL20 blockade increases the severity of nephrotoxic folic acid-induced acute kidney injury.
González-Guerrero C; Morgado-Pascual JL; Cannata-Ortiz P; Ramos-Barron MA; Gómez-Alamillo C; Arias M; Mezzano S; Egido J; Ruiz-Ortega M; Ortiz A; Ramos AM
J Pathol; 2018 Oct; 246(2):191-204. PubMed ID: 29984403
[TBL] [Abstract][Full Text] [Related]
17. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
[TBL] [Abstract][Full Text] [Related]
18. CCL20/CCR6 promotes cell proliferation and metastasis in laryngeal cancer by activating p38 pathway.
Lu E; Su J; Zhou Y; Zhang C; Wang Y
Biomed Pharmacother; 2017 Jan; 85():486-492. PubMed ID: 27916417
[TBL] [Abstract][Full Text] [Related]
19. CCL20/CCR6 promotes the invasion and migration of thyroid cancer cells via NF-kappa B signaling-induced MMP-3 production.
Zeng W; Chang H; Ma M; Li Y
Exp Mol Pathol; 2014 Aug; 97(1):184-90. PubMed ID: 24984269
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis.
Liu W; Wang W; Wang X; Xu C; Zhang N; Di W
Cancer Lett; 2020 Mar; 472():59-69. PubMed ID: 31866467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
